Calistoga Drug Shrinks Tumors as Study Grows

Xconomy Seattle — 

Calistoga Pharmaceuticals, the Seattle-based biotech company, said today that its lead drug in development was able to at least partially shrink tumors in 12 of the first 24 patients with blood cancers in a clinical trial. The data were presented today at the European Hematology Association meeting in Berlin, Germany. This finding buttresses some more preliminary results we reported on last week from the American Society of Clinical Oncology, in which six of the first 12 patients on the Calistoga drug had partial tumor shrinkage.